0001193125-23-011988.txt : 20230120 0001193125-23-011988.hdr.sgml : 20230120 20230120160558 ACCESSION NUMBER: 0001193125-23-011988 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230119 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20230120 DATE AS OF CHANGE: 20230120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 23541011 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: PROGENITY, INC. DATE OF NAME CHANGE: 20150617 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 8-K 1 d424427d8k.htm 8-K 8-K
false 0001580063 0001580063 2023-01-19 2023-01-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 19, 2023

 

 

Biora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39334   27-3950390
(State or Other Jurisdiction
of Incorporation)		  

(Commission

File Number)

   (IRS Employer
Identification No.)

 

4330 La Jolla Village Drive, Suite 300  
San Diego, California   92122
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (833) 727-2841

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   BIOR   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 19, 2023, Biora Therapeutics, Inc. (the “Company”) received a letter (the “Compliance Letter”) from Nasdaq notifying the Company that (i) the Company’s previously announced bid price deficiency had been cured and (ii) the Company was in compliance with all applicable continued listing standards. Accordingly, the Compliance Letter provided that the Company’s scheduled hearing had been cancelled. As previously disclosed, in December 2022, the Company received a determination from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that, due to the Company’s continued bid price deficiency, the Company’s securities were subject to delisting unless the Company timely requested a hearing before the Nasdaq Hearings Panel. The Company’s common stock will continue to be listed and traded on The Nasdaq Global Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      Biora Therapeutics, Inc.
Date: January 20, 2023     By:  

/s/ Eric d’Esparbes

      Eric d’Esparbes
Chief Financial Officer
 EX-101.SCH 2 bior-20230119.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 bior-20230119_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 4 bior-20230119_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Jan. 19, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001580063
Document Type 8-K
Document Period End Date Jan. 19, 2023
Entity Registrant Name Biora Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39334
Entity Tax Identification Number 27-3950390
Entity Address, Address Line One 4330 La Jolla Village Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (833)
Local Phone Number 727-2841
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol BIOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 6 d424427d8k_htm.xml IDEA: XBRL DOCUMENT 0001580063 2023-01-19 2023-01-19 false 0001580063 8-K 2023-01-19 Biora Therapeutics, Inc. DE 001-39334 27-3950390 4330 La Jolla Village Drive Suite 300 San Diego CA 92122 (833) 727-2841 false false false false Common Stock, par value $0.001 per share BIOR NASDAQ true false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d424427d8k.htm bior-20230119.xsd bior-20230119_lab.xml bior-20230119_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d424427d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d424427d8k.htm" ] }, "labelLink": { "local": [ "bior-20230119_lab.xml" ] }, "presentationLink": { "local": [ "bior-20230119_pre.xml" ] }, "schema": { "local": [ "bior-20230119.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bior", "nsuri": "http://bioratherapeutics.com/20230119", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d424427d8k.htm", "contextRef": "duration_2023-01-19_to_2023-01-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d424427d8k.htm", "contextRef": "duration_2023-01-19_to_2023-01-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://bioratherapeutics.com//20230119/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001193125-23-011988-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-011988-xbrl.zip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end